News Release

Metabolomic Analysis Method Adopts NuGel™-HemogloBind™ in Study of Adults with Epilepsy

MONMOUTH JUNCTION, NJ, February 16, 2023 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of NuGel™ HemogloBind™, to remove Hemoglobin interference, in a LC-MS metabolomic analysis of plasma in a dietary study of adults with epilepsy.

The citation is:

Leitner, Dominique F., et al. "Metabolomic, Proteomic, and Transcriptomic Changes in Adults with Epilepsy on Modified Atkins Diet." Epilepsia (2023).

High fat and low carbohydrate diets can reduce seizure frequency in some treatment-resistant epilepsy patients, including the more flexible Modified Atkins Diet (MAD). Low carbohydrate diets may shift brain energy production, particularly impacting neuron and astrocyte linked metabolism. The study evaluated the effect of short-term MAD on molecular mechanisms in adult epilepsy patients from surgical brain tissue and plasma compared to Control participants consuming a non-modified higher carbohydrate diet. For Plasma Metabolomics, the article states “Whole blood was thawed on ice and processed to remove hemoglobin by NuGel-HemogloBind according to manufacturer protocol…samples were analyzed with the hybrid LCMS assay after scaling metabolite extraction to 100ul/sample.”. The article concludes that Short-term MAD was associated with metabolic differences in plasma and resected epilepsy brain tissue when compared to Control participants; there were 13 increased metabolites in plasma that included 4.10-fold increased ketone body 3-hydroxybutyric acid, decreased palmitic acid in cortex, and 11 decreased metabolites in hippocampus, that had top associations with mitochondrial functions.

“Here is another example of the versatility of NuGel™ HemogloBind™, as it is used here to clear interference in LC-MS metabolomic analysis. While NuGel™ HemogloBind™ is intended specifically for Hemoglobin removal, a related product - NuGel™ BindPro™, also can fulfill the function of a general aqueous protein crash reagent for metabolomic analysis.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group. 

Click here for more information on NuGel™ HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Click here for more information on NuGel™ BindPro™

Keywords: Epilepsy, Modified Atkins Diet, metabolomics, NuGel™ HemogloBind™, NuGel™ BindPro™, aqueous protein crash

About Biotech Support Group LLC

Converging with technological disruptions forthcoming in healthcare, Biotech Support Group continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com